| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1008387753 |
| P356 | DOI | 10.1186/1869-5760-3-48 |
| P2888 | exact match | https://scigraph.springernature.com/pub.10.1186/1869-5760-3-48 |
| P932 | PMC publication ID | 3695808 |
| P698 | PubMed publication ID | 23724805 |
| P5875 | ResearchGate publication ID | 237001087 |
| P2093 | author name string | Denis Wakefield | |
| Peter J McCluskey | |||
| William B Yates | |||
| P2860 | cites work | Long-lasting remission of Behcet's disease after chlorambucil therapy | Q28364136 |
| Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials | Q33243658 | ||
| Overall and cancer related mortality among patients with ocular inflammation treated with immunosuppressive drugs: retrospective cohort study | Q33478325 | ||
| The occurrence of malignancies in patients with rheumatoid arthritis treated with cyclophosphamide: a controlled retrospective follow-up | Q33554543 | ||
| Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: a 20 year follow up study | Q33561291 | ||
| Management of chronic uveitis | Q33846063 | ||
| Post-transplant malignancy: the role of immunosuppression | Q34005794 | ||
| Effects of cyclophosphamide on the development of malignancy and on long‐term survival of patients with rheumatoid arthritis a 20‐year followup study | Q34302518 | ||
| Malignancy in Behçet's disease: a report of 13 cases and a review of the literature | Q34350996 | ||
| Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-cont | Q34547981 | ||
| Skin cancers after organ transplantation | Q35113533 | ||
| Cicatricial pemphigoid | Q68158346 | ||
| Cancers after cyclosporine therapy | Q68426571 | ||
| Cancers following cyclosporine therapy | Q69707718 | ||
| Skin cancer and immunosuppression | Q70033555 | ||
| The risk of skin cancer in renal transplant recipients in Queensland, Australia. A follow-up study | Q71015106 | ||
| Cancers in cyclosporine-treated vs azathioprine-treated patients | Q71063139 | ||
| Immunosuppressive therapy for external ocular inflammatory disease | Q72137541 | ||
| Immunosuppression and risk of non-melanoma skin cancer in renal transplant recipients | Q73073923 | ||
| Systemic immunosuppressive therapy and the occurrence of malignancy in patients with ocular inflammatory disease | Q73211674 | ||
| The incidence of cancer associated with the treatment of rheumatoid arthritis | Q73327826 | ||
| Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens | Q74455780 | ||
| Tacrolimus (FK506) in the treatment of posterior uveitis refractory to cyclosporine | Q77319364 | ||
| Risk of developing certain malignancies is related to duration of immunosuppressive drug exposure in patients with rheumatic diseases | Q78139435 | ||
| Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed | Q35554130 | ||
| Risk of malignant neoplasms in patients with pulmonary sarcoidosis | Q35563178 | ||
| Lymphoproliferative disorders in Sjögren's syndrome | Q35756957 | ||
| Rates of malignancy associated with juvenile idiopathic arthritis and its treatment | Q35861269 | ||
| Incidence of cancer after immunosuppressive treatment for heart transplantation. | Q36175252 | ||
| Post-transplant de novo malignancies in renal transplant recipients: the past and present | Q36530274 | ||
| Biologics in the treatment of uveitis | Q37046546 | ||
| Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases | Q37404893 | ||
| HIV-related malignancies pre- and post-highly active antiretroviral therapy: experiences in an inner city tertiary referral centre. | Q37760365 | ||
| Malignancy after renal transplantation: the role of immunosuppression | Q37782262 | ||
| Pharmacologic Immunomodulation and Cutaneous Malignancy in Rheumatoid Arthritis, Psoriasis, and Psoriatic Arthritis | Q37784601 | ||
| Malignancy as a comorbidity in rheumatic diseases | Q38029322 | ||
| Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with methotrexate | Q38456142 | ||
| Cancer is a complication of severe immunosuppression. | Q39734950 | ||
| KDIGO clinical practice guideline for the care of kidney transplant recipients | Q39936865 | ||
| The price of immunotherapy | Q40262975 | ||
| Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment | Q42434922 | ||
| Malignancy after renal transplantation: analysis of incidence and risk factors in 1700 patients followed during a 25-year period | Q42437452 | ||
| Incidence of skin cancer after renal transplantation in The Netherlands. | Q42483958 | ||
| Incidence of skin cancer in 5356 patients following organ transplantation | Q42492822 | ||
| Risk factors for basal cell carcinoma | Q42495527 | ||
| Solid tumors after heart transplantation: lethality of lung cancer | Q42522591 | ||
| A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients | Q43604925 | ||
| Neoplastic consequences of transplantation and chemotherapy. | Q43622090 | ||
| Lung cancer after heart transplantation: results from a large multicenter registry | Q43685859 | ||
| p53 mutations implicate sunlight in post-transplant skin cancer irrespective of human papillomavirus status | Q43903162 | ||
| Malignancy after renal transplantation in the new era of immunosuppression. | Q43983994 | ||
| Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study. | Q44287692 | ||
| Behçet's disease associated with a lymphoproliferative disorder, mixed cryoglobulinemia, and an immune complex mediated vasculitis | Q44466567 | ||
| Treatment of ocular mucous membrane pemphigoid with immunosuppressive drug therapy | Q46310362 | ||
| A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. | Q46595124 | ||
| Methotrexate vs. ciclosporin in psoriasis: effectiveness, quality of life and safety. A randomized controlled trial | Q46912129 | ||
| Does exposure to immunosuppressive therapy increase the 10 year malignancy and mortality risks in rheumatoid arthritis? A matched cohort study. | Q51016312 | ||
| Enhancement of UV-induced skin carcinogenesis by azathioprine: role of photochemical sensitisation. | Q53517667 | ||
| Sirolimus and secondary skin-cancer prevention in kidney transplantation. | Q55056496 | ||
| Collaborative United Kingdom-Australasian study of cancer in patients treated with immunosuppressive drugs | Q55652491 | ||
| Rheumatoid arthritis and cancer risk | Q57422965 | ||
| Relationship between current level of immunodeficiency and non-acquired immunodeficiency syndrome-defining malignancies | Q57877211 | ||
| A BLINDED, LONG-TERM, RANDOMIZED MULTICENTER STUDY OF MYCOPHENOLATE MOFETIL IN CADAVERIC RENAL TRANSPLANTATION | Q57985174 | ||
| Malignancy following treatment of rheumatoid arthritis with cyclophosphamide | Q59647405 | ||
| Incidence of malignant disease in biopsy-proven inflammatory myopathy. A population-based cohort study. | Q61649125 | ||
| Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis | Q67429351 | ||
| P433 | issue | 1 | |
| P921 | main subject | eye disease | Q3041498 |
| P304 | page(s) | 48 | |
| P577 | publication date | 2013-05-31 | |
| P1433 | published in | Journal of ophthalmic inflammation and infection | Q27723542 |
| P1476 | title | Are patients with inflammatory eye disease treated with systemic immunosuppressive therapy at increased risk of malignancy? | |
| P478 | volume | 3 |
Search more.